Forbes January 23, 2025
Alex Knapp

A temporary freeze on meetings on the National Institutes of Health could lead to delays in disbursing research grants and in approving crucial clinical trials.

Yesterday, the Trump Administration imposed a wide range of restrictions on the National Institutes of Health (NIH): a pause on all external communications, a hiring freeze, a travel ban and, perhaps most crucially, the cancellation of grant review panels, until at least February 1. These panels, where a team of NIH experts review research proposals, are required before the $47.4 billion agency will disburse money to support research by hospitals, universities and biotech companies.

The biggest chunk of this money goes toward cancer research. The NIH’s budget has a $7.1 billion annual budget for the...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Pharma / Biotech
Podcast: How Trump’s tariffs will impact clinical trials
As States Mull Medicaid Work Requirements, Two Scale Theirs Back
Are Diet and Exercise the Keys to Longevity? Think Again, Expert Tells Senators
President’s Day Weekend Firings At Government Agencies Within HHS
STAT+: FDA cuts hit AI division, even as Trump invests in the technology

Share This Article